Zacks Research Upgrades Delcath Systems (NASDAQ:DCTH) to “Strong-Buy”

Delcath Systems (NASDAQ:DCTH) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research firms have also issued reports on DCTH. BTIG Research lifted their target price on Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $23.17.

Delcath Systems Stock Up 3.3%

Shares of NASDAQ:DCTH opened at $17.22 on Monday. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $17.42. The stock has a market cap of $597.52 million, a P/E ratio of 1,723.72 and a beta of 0.52. The business’s 50 day moving average is $12.61 and its 200 day moving average is $10.97.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. The company had revenue of $29.13 million during the quarter, compared to analyst estimates of $26.25 million. On average, sell-side analysts anticipate that Delcath Systems will post -0.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DCTH. California State Teachers Retirement System acquired a new position in Delcath Systems during the 2nd quarter valued at about $26,000. Russell Investments Group Ltd. acquired a new stake in Delcath Systems in the third quarter worth about $29,000. Tower Research Capital LLC TRC acquired a new stake in Delcath Systems in the second quarter worth about $40,000. Legal & General Group Plc purchased a new stake in shares of Delcath Systems during the second quarter worth about $46,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Delcath Systems during the second quarter worth about $151,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems News Roundup

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $32 price target while sharply raising its EPS forecasts. The firm now expects a smaller FY2026 loss of $0.17 per share, versus its prior estimate of $0.88, followed by profitability in FY2027 at $0.12 per share. Longer-term estimates were also increased to $0.56 for FY2028, $0.97 for FY2029 and $1.46 for FY2030, suggesting improved confidence in Delcath’s earnings trajectory. MarketBeat analyst estimates
• Positive Sentiment: Zacks highlighted DCTH as a potential momentum stock, citing favorable price momentum and improving earnings-estimate revisions. Another Zacks analysis said Wall Street analysts see potential upside of approximately 42.8%, although price-target projections are not guaranteed. Zacks momentum stock analysis Zacks price target analysis
• Neutral Sentiment: Reported short interest was zero shares both on August 11 and July 27, producing a zero-day short-interest ratio. Because the report also shows an invalid “NaN” change, the data provides no meaningful indication of short-covering or bearish pressure.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.